Literature DB >> 30806966

Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".

Georgios Tsivgoulis1,2, Lina Palaiodimou3, Aristeidis H Katsanos3,4, Konstantinos Voumvourakis3, Georgios M Hadjigeorgiou5, Ioannis Heliopoulos6, Theodore Karapanayiotides7, Panagiotis Papathanasopoulos8, Constantinos Kilidireas9, Nikolaos Grigoriadis7.   

Abstract

Year:  2019        PMID： 30806966     DOI： 10.1007/s40263-019-00615-5

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  1 in total

1.  Authors' Reply to Tsivgoulis et al.: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".

Authors:  Dimitrios Papadopoulos; Dimos-Dimitrios D Mitsikostas
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.